{"id":"gsk573719-gw642444-125-25","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Muscle cramps"},{"rate":null,"effect":"Nervousness"}]},"_chembl":{"chemblId":"CHEMBL3646855","moleculeType":"Protein","molecularWeight":"1151.77"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GSK573719 (umeclidinium) is a LAMA that blocks muscarinic M3 receptors on airway smooth muscle, preventing bronchoconstriction. GW642444 (vilanterol) is a LABA that activates beta-2 adrenergic receptors, causing bronchodilation. Together, these complementary mechanisms provide sustained airway relaxation and improved lung function in COPD patients.","oneSentence":"GSK573719/GW642444 is a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta-2 agonist (LABA) that relaxes airway smooth muscle and reduces mucus secretion to improve airflow in chronic obstructive pulmonary disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:40.242Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT01316887","phase":"PHASE3","title":"A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-01-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":563},{"nctId":"NCT01323660","phase":"PHASE3","title":"An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03-16","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":307},{"nctId":"NCT01316900","phase":"PHASE3","title":"24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":846},{"nctId":"NCT01328444","phase":"PHASE3","title":"An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":349},{"nctId":"NCT01691547","phase":"PHASE1","title":"A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-12-17","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":44},{"nctId":"NCT01521377","phase":"PHASE1","title":"QTc Study GSK573719+GW642444","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-12-19","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":100},{"nctId":"NCT01894386","phase":"PHASE1","title":"Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-07-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":48},{"nctId":"NCT01316913","phase":"PHASE3","title":"24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":872},{"nctId":"NCT01636713","phase":"PHASE3","title":"A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo in Subjects With COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":581},{"nctId":"NCT01376388","phase":"PHASE3","title":"Long-term Safety Study for GSK573719/GW642444 in Japanese","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-08","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":131}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GSK573719/vilanterol trifenatate"],"phase":"phase_3","status":"active","brandName":"GSK573719/GW642444 125/25","genericName":"GSK573719/GW642444 125/25","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GSK573719/GW642444 is a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta-2 agonist (LABA) that relaxes airway smooth muscle and reduces mucus secretion to improve airflow in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}